Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons [PublishAheadOfPrint]

Although genotype (GT) 4-infected patients represent a minor overall percentage of the global hepatitis C virus (HCV)-infected population, the high prevalence of the genotype in specific geographic regions coupled with substantial sequence diversity makes it an important genotype to study for antiviral drug discovery and development. We evaluated two direct-acting antiviral agents: grazoprevir, an HCV NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, in GT4 replicons prior to clinical studies in this genotype. Following a bioinformatics analysis of available GT4 sequences, a set of replicons bearing representative GT4 clinical isolates was generated. For grazoprevir, the EC₅₀ value against the replicon bearing the reference GT4a (ED43) NS3 protease and NS4A was 0.7 nM. The median EC₅₀ value for grazoprevir against chimeric replicons encoding NS3/4A sequences from GT4 clinical isolates was 0.2 nM (range 0.11-0.33 nM; N=5). The difficulty in establishing replicons bearing NS3/4A resistance-associated substitutions was substantially overcome with the identification of a G162R adaptive substitution in NS3. Single NS3 substitutions D168A/V identified from de novo resistance selection studies reduced grazoprevir antiviral activity by 137- and 47-fold, respectively in the background of the G162R replicon. For elbasvir, the EC₅₀ value against the replicon bearing the reference full-length GT4a (ED43) NS5A gene was 0.0002 nM. The median EC₅₀ value for elbasvir against chimeric replicons bearing clinical isolates from GT4 was 0.0007 nM (range 0.0002-34 nM; N=14). De novo resistance selection studies in GT4 demonstrated a high propensity to suppress the emergence of amino acid substitutions that confer high potency reductions to elbasvir. Phenotypic characterization of the NS5A amino acid substitutions identified (L30F/S, M31V and Y93H) indicated they conferred 15-, 4-, 2.5- and 7.5-fold potency losses respectively to elbasvir. The activity profiles of grazoprevir and elbasvir supported the testing of the direct-acting antivirals in clinical studies.

http://ift.tt/2oGg6kd